Alternative anticoagulation with danaparoid in two pregnancies in a patient with former heparin-induced thrombocytopenia (HIT), homozygous factor V Leiden mutation, a history of venous thrombosis and recurrent pregnancy losses

 

This study was presented at the XXI^st Congress of the International Society on Thrombosis and Haemostasis in Geneva, July 06–12, 2007.

• References

• 1 Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005; 93: 63-69.
• 2 Schindewolf M, Mosch G, Bauersachs RM. et al. Safe anticoagulation with danaparoid in pregnancy and lactation. Thromb Haemost 2004; 92: 211.
• 3 Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 967-981.
• 4 Schindewolf M, Daemgen-von-Brevern G, Mani H. et al. Alternative anticoagulation with fondaparinux in pregnant patients with heparin-intolerance. Haemostaseologie 2007; 27: 69-70.
• 5 Harenberg J, Jörg I, Bayerl C. et al. Treatment of a woman with lupus pernio, thrombosis and cutaneous intolerance to heparins using lepirudin during pregnancy. Lupus 2005; 14: 411-412.
• 6 Warkentin TE, Chong BH, Greinacher A. Heparininduced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
• 7 Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost 2007; 97: 505-513.